Picamilon
Pikamilon · Pikatropin · N-nicotinoyl-GABA · nicotinoyl-γ-aminobutyric acid · nicotinyl-GABA
Last updated
At a glance
Overview
What Picamilon Actually Does#
Picamilon is a covalent conjugate of GABA and niacin — a Soviet-era neurology drug that solved a real pharmacological problem: free GABA can't cross the blood–brain barrier, and free niacin floods the systemic circulation before it ever reaches cerebral vessels. Linking the two as a single lipophilic molecule lets both halves arrive in the CNS intact, where central amidases cleave them apart. The result is a clean two-channel effect — mild GABA-A anxiolysis layered on top of focal cerebral vasodilation — that the nootropic and looksmaxxing community reaches for as a "phenibut without the phenibut problem" tool.
The cerebrovascular signature is what separates picamilon from every other GABAergic on the shelf. Mirzoyan and Gan'shina documented marked cerebral-vessel dilation and elevated cerebral blood flow in both intact and ischemic brain tissue, and follow-up work by Silkina established that the vasodilation is itself GABA-A dependent — picrotoxin abolishes it.
"Pikamilon produced a marked vasodilatory effect on cerebral vessels and increased cerebral blood flow in both intact and ischemic brain." — Mirzoyan & Gan'shina, Farmakologiia i Toksikologiia (1989)
Physique-focused users typically deploy picamilon in one of three lanes: on-cycle anxiolysis for managing the sympathetic overdrive of heavy androgens or aggressive cuts, pre-event calm focus ahead of cardio, photo shoots, or stage check-ins, and as the vascular component of a racetam/choline nootropic stack where the cerebral perfusion boost makes the cholinergic side actually perform. The sections below cover documented picamilon dose ranges, oral protocol design, cycling and tolerance management, stacking with L-theanine, racetams, and adaptogens, side effects, and the sourcing pitfalls created by the FDA's 2015 supplement ruling.
How Picamilon works
Picamilon is a deceptively simple molecule — GABA and niacin (nicotinic acid) joined by an amide bond — but that single covalent link solves the central problem that defeats both parents on their own. Free GABA does not cross the blood-brain barrier in pharmacologically meaningful quantities, and oral niacin produces a systemic flush long before it reaches cerebral tissue. The conjugate is lipophilic enough to traverse the BBB intact and is then cleaved by central amidases into its two active fragments, releasing both payloads exactly where they're useful.
Blood-Brain Barrier Transit as a Prodrug#
The nicotinoyl-GABA amide is the entire point of the molecule. Once across the BBB, hydrolytic cleavage liberates GABA on one side and nicotinic acid on the other, producing a localized rise in both species inside CNS tissue rather than in peripheral circulation. This is why the subjective profile is "cerebral" — focal warmth, mental quiet, light pressure relief — rather than the whole-body flush of plain niacin. For physique-focused users, the practical translation is that picamilon delivers anxiolysis without the cognitive flattening of peripheral GABAergics and without the skin flush of nutritional-dose niacin.
GABA-A Receptor Activity#
The liberated GABA acts at GABA-A receptors, generating the mild anxiolytic and relaxant signature. Critically, this is a chloride-channel mechanism rather than benzodiazepine-site binding — which is why picamilon does not produce benzodiazepine-style amnesia, ataxia, or the dependence trajectory that defines phenibut (a GABA-B agonist). Silkina and colleagues established the GABA-A dependence of picamilon's central effects by abolishing them with picrotoxin, a GABA-A chloride-channel blocker.
"When picrotoxin, a blocker of the GABA-A receptor chloride channel, was administered, the effect of nicotinoyl-GABA on cerebral circulation was abolished." — Silkina I.V. et al., Eksp Klin Farmakol, 2005
For the on-cycle user managing sympathetic overdrive from heavy androgens, harsh cuts, or stimulant-laden pre-workouts, this translates to a clean downshift in anticipatory anxiety without sedation or next-day fog.
Cerebrovascular Vasodilation#
The niacin moiety drives a niacin-style vasodilation, but the response is anatomically biased toward cerebral vessels and is itself GABA-A-mediated rather than purely prostaglandin-driven. Mirzoyan and Gan'shina demonstrated that this is not a marginal effect.
"Pikamilon produced a marked vasodilatory effect on cerebral vessels and increased cerebral blood flow in both intact and ischemic brain." — Mirzoyan R.S., Gan'shina T.S., Farmakologiia i Toksikologiia, 1989
Increased cerebral perfusion is the mechanistic basis for picamilon's reputation as a "focus enhancer" and for its synergy with racetams, which are presumed to demand higher cerebral metabolic throughput than they can sustain on their own. The practical outcome is cleaner concentration during cognitively demanding training contexts — programming, posing practice, contest prep math — without the wired edge of stimulant focus.
Autoregulatory Normalization and Neuroprotection#
Beyond acute vasodilation, picamilon appears to restore the brain's own autoregulation of blood flow after ischemic insult. Lukyanova and colleagues documented this in models of transient cerebral ischemia.
"Pikamilon administration led to a significant normalization of cerebral blood flow autoregulation after transient ischemia." — Lukyanova L.D. et al., Eksp Klin Farmakol, 1999
Mirzoyan's later work generalized the finding across ischemia and hypoxia models, framing picamilon as a cerebrovascular protectant rather than a pure vasodilator.
"Picamilon demonstrated a pronounced cerebrovascular action, improving outcomes in models of cerebral ischemia and hypoxia." — Mirzoyan R.S. et al., Annals of Clinical and Experimental Neurology, 2018
This is the mechanism behind the long-standing Russian clinical use of picamilon in post-stroke recovery, vascular cephalgia, and chronic cerebrovascular insufficiency — and it is also the rationale for the migraine-prophylaxis protocols that have filtered into the nootropic community.
Practical Synthesis#
| Mechanism | Liberated agent | Functional outcome |
|---|---|---|
| BBB-permeable prodrug delivery | nicotinoyl-GABA intact | Central effects without peripheral flush |
| GABA-A chloride channel | GABA | Anxiolysis, sympathetic downshift, no dependence trajectory |
| Cerebral vasodilation (GABA-A–mediated) | nicotinic acid | Increased CBF, sharper focus, racetam synergy |
| Autoregulatory restoration | combined | Neuroprotection, vascular-headache prophylaxis |
The two payloads work in opposite directions on the autonomic axis — GABA quiets, niacin opens — and the net effect is a "calm but perfused" state that is hard to reproduce with any single-mechanism nootropic. That is the entire reason picamilon has held its niche for fifty years despite being structurally trivial.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 50–100 mg | Twice daily | Documented entry-level range |
| Mid | 100–200 mg | Twice daily | Most commonly studied range |
| High | 200–300 mg | Twice daily | Split AM + early PM for daily anxiolytic use. Single dose 60–90 minutes pre-event for acute use. Onset is too slow for sleep-onset — dose 60–90 minutes pre-bed if used for wind-down. |
Cycle length & outcomes
Documented cycle
4–8 weeks
Plateau after
6 wks
Cycle Structure & Onset#
Picamilon is one of the simpler nootropics to schedule — no loading phase, no taper, no PCT, and no endocrine footprint. The cycling logic is built around GABA-A receptor tolerance, not dependence. Continuous daily dosing past ~6 weeks blunts the anxiolytic component; a 1–2 week washout restores it cleanly.
| Goal | Cycle Length | Daily Dose | Schedule |
|---|---|---|---|
| Acute pre-event calm focus | As-needed | 100–150mg | Single dose, 60–90 min pre-event |
| Daily on-cycle anxiolysis | 4–6 weeks | 100–200mg | Split AM + early PM |
| Cognitive / focus stack (with racetam + choline) | 4–6 weeks | 100–200mg | AM, with stack |
| Pre-bed wind-down | As-needed or 4 weeks | 50–100mg | 60–90 min pre-bed |
| Vascular-headache prophylaxis | 4–8 weeks | 100–150mg | 50mg × 2–3 daily |
Onset Timing#
Oral onset runs 30–60 minutes, with subjective effects building over 1–2 hours and peaking around the 2-hour mark. Total functional duration is 4–6 hours of clearly perceptible effect, trailing off with a residual mild calm afterwards. This is fast enough for pre-event use but too slow for sleep onset — anyone using it as a wind-down tool should dose 60–90 minutes before bed rather than at lights-out.
The cerebrovascular component (niacin moiety) is what gives picamilon its characteristic "clear-headed" anxiolysis rather than the foggy sedation of pure GABAergics. Mirzoyan and Gan'shina documented the vascular signature directly:
"Pikamilon produced a marked vasodilatory effect on cerebral vessels and increased cerebral blood flow in both intact and ischemic brain." — Mirzoyan & Gan'shina, Farmakologiia i Toksikologiia (1989)
Loading and Tapering#
No loading is required. Unlike racetams, picamilon does not need a build-up period — the parent compound is hydrolyzed centrally into GABA + niacin within hours of administration, and effects are present from the first dose. The 50mg entry dose exists to gauge individual response, not to load receptors.
No taper is required. Picamilon does not produce a phenibut-style withdrawal syndrome at standard doses. A clean stop at the end of a 4–6 week block is the standard approach. The 1–2 week off period exists to restore GABA-A receptor sensitivity, not to manage discontinuation symptoms.
Cycle Duration Logic#
The 4–8 week ceiling is set by tolerance, not toxicity. Russian neurology practice runs picamilon for 1–2 months continuously in cerebrovascular insufficiency protocols, and that upper bound translates well to nootropic use. Past 6–8 weeks of daily dosing, most users report the anxiolytic edge dulls; the cerebrovascular effect persists longer but isn't worth running in isolation.
The cerebrovascular mechanism that drives the cognitive component holds up under repeated dosing, per Lukyanova's autoregulation work:
"Pikamilon administration led to a significant normalization of cerebral blood flow autoregulation after transient ischemia." — Lukyanova et al., Eksp Klin Farmakol (1999)
For users running picamilon purely as-needed for events, photoshoots, or pre-cardio calm, no cycle structure is required at all — single doses can be spaced indefinitely without tolerance accumulation.
Bloodwork Cadence#
Picamilon has no endocrine footprint — no HPTA suppression, no aromatase activity, no 5-AR interaction, no impact on lipids or hematocrit at standard doses. Routine bloodwork specifically for picamilon use is not warranted.
The one realistic monitoring concern is cumulative niacin load for users stacking picamilon with flush-niacin lipid protocols, niacin-containing pre-workouts, or running 200+ mg/day for the full 6–8 week block. In that combined-niacin scenario, a liver panel (ALT/AST) at the 4-week mark of a long block is reasonable — the concern is the additive niacin exposure, not picamilon itself.
For users running picamilon alongside an active AAS cycle, the standard on-cycle bloodwork cadence (lipids, CMP, CBC at 6–8 week intervals) covers everything picamilon could plausibly perturb.
Practical Cycle Notes#
- Stack onboarding: When layering picamilon into an existing nootropic stack (racetam + choline, theanine + caffeine, ashwagandha), introduce it alone first at 100mg for 2–3 days to identify the picamilon signature before re-adding the rest.
- Dose timing: Split doses (AM + early PM) outperform single large doses for daily anxiolytic use. The PM half is dosed by ~3 PM to avoid trailing residual calm into evening training.
- Off-period stacking: During the 1–2 week washout, L-theanine, magnesium glycinate, and ashwagandha cover the anxiolytic gap without re-engaging GABA-A.
- Re-initiation: After a washout, the protocol restarts at the previous effective dose — no need to re-titrate from 50mg.
The short half-life of the parent compound, the lack of dependence liability, and the absence of endocrine effects mean picamilon is one of the lowest-friction nootropics to schedule around a training cycle. The cycle structure exists almost entirely to preserve efficacy, not to manage risk.
Risks & mistakes
Common (most users)#
- Niacin-style flush — warmth, mild scalp tingling, occasional facial pinkness, typically at single doses above 150mg. Far milder than oral flush-niacin because the GABA conjugate localizes vasodilation toward cerebral vessels. Mitigation: dose with food, split AM/PM rather than loading 200mg+ at once, or drop to 100mg per administration.
- Mild headache — most often at initiation or at the upper end of the dose range. Usually self-resolving within 2–3 days as cerebrovascular tone adjusts. Mitigation: start at 50mg for the first 2–3 administrations to gauge response before titrating up.
- Light-headedness on standing — the niacin moiety adds mild systemic vasodilation. Mitigation: hydration, electrolytes, and not stacking with other vasodilators in the same window (high-dose citrulline pre-workouts, daily tadalafil, sildenafil).
- Transient nausea on empty stomach — minority of users. Pairing with a light meal resolves it.
- Mild GI upset — niacin component can aggravate sensitive stomachs. Food pairing handles it.
Uncommon (dose-dependent or individual)#
- Paradoxical irritability or restlessness — typically a signal the dose is too high for the individual's GABAergic sensitivity. Drop one tier (200mg → 100mg) rather than push through it.
- Sedation or "fog" above ~200mg in GABA-sensitive subjects. Picamilon should feel like a calm focus tool; if it feels like phenibut-lite, the dose is wrong for that user.
- Additive hypotension when stacked with PDE5 inhibitors, antihypertensives, or heavy NO-donor pre-workouts. Spacing doses (picamilon AM, tadalafil PM) is the standard workaround. If resting BP runs low to begin with, monitor before pushing the upper dose range.
- Tolerance to the anxiolytic effect on continuous daily multi-week protocols. Cycle structure (4–8 weeks on, 1–2 weeks off) restores responsiveness. No physical-dependence syndrome documented at standard doses — unlike phenibut.
- Elevated cumulative niacin load in protocols stacking picamilon with flush-niacin lipid stacks or niacin-heavy pre-workouts. LFTs are worth checking on any 6+ week block at 200mg+/day combined with other niacin sources.
"Among the supplements tested, picamilon content per serving ranged from 2.7 mg to 721 mg, calling into question the reliability of product labeling." — Cohen et al., Clinical Toxicology (2015)
The single biggest practical risk in this market is product variance, not pharmacology. A 400-fold range across supposedly identical capsules means a "100mg" cap from a no-COA vendor can deliver anything from inert to a 700mg slug. COA-publishing vendors only.
Rare but serious#
- Severe orthostatic hypotension when combined with nitrates or stacked with PDE5 inhibitors plus NO donors. Warning signs: graying vision on standing, syncope. Discontinue and reassess the stack.
- Sustained tachycardia or chest discomfort — rare, but worth stopping for. The mechanism would be excessive systemic vasodilation in a susceptible cardiovascular profile, not a direct picamilon toxicity.
- Hepatotoxicity signal on long-running high-dose protocols, particularly when stacked with other niacin sources or hepatotoxic compounds (orals, isotretinoin). Warning signs: RUQ discomfort, jaundice, dark urine. Discontinue and pull LFTs.
- Mood destabilization in bipolar-spectrum subjects — GABAergic agents can flip into disinhibition or trigger mood cycling. Warning sign is any qualitative shift in mood pattern; discontinue at first sign.
Hard contraindications#
- Pregnancy and lactation — no teratogenicity data exists. Not appropriate for subjects with pregnancy potential.
- PDE5 inhibitors plus nitrates — the hard rule (severe hypotension) is unchanged by picamilon. Picamilon adds vasodilatory tone on top of an already-prohibited combination.
- Severe hepatic dysfunction — impaired clearance of the niacin moiety and its metabolites.
- Severe renal dysfunction — same rationale.
- Active peptic ulcer disease — the niacin component aggravates GI mucosa.
- Bipolar disorder — GABAergic disinhibition risk.
- Concurrent phenibut use — additive GABAergic load on top of phenibut's GABA-B agonism gets sloppy fast and undermines the reason most users choose picamilon (avoiding the phenibut profile).
Gender and endocrine considerations#
No gender-specific dosing adjustments are documented. Picamilon has no endocrine activity — no HPTA suppression, no aromatase or 5-AR interaction, no androgenic or estrogenic signal. It is appropriate during cycle, cruise, or PCT, and PCT is not required following picamilon use. For subjects with pregnancy potential, the absence of teratogenicity data makes it inappropriate regardless of cycle phase. Unlike phenibut, no clinically recognized withdrawal syndrome is documented at standard doses, and the FDA's public adverse-event file on picamilon was empty at the time of the 2015 enforcement action — the regulatory action was based on its status as a synthetic drug, not on safety reports.
FAQ — Picamilon
Research & citations
5 studies cited on this page.
Conclusion
Picamilon fills a unique slot in the nootropic toolkit: it delivers mild GABAergic calm with real cerebrovascular support, making it a go-to for anxiolytic focus without the dependence risks of phenibut or the sedation of benzodiazepines.
Key takeaways:
- Typical dose: 100–200 mg/day, split into AM and early PM (oral)
- Acute protocol: 100–150 mg, dosed 60–90 minutes pre-event or pre-cardio for calm, focused energy
- Cycle duration: 4–8 weeks, then 1–2 weeks off to reset tolerance
- Stacks cleanly with racetams, choline donors, L-theanine, and adaptogens for cognitive or stress-management protocols
- Vasodilates cerebral vessels and normalizes cerebral blood flow — supported by multiple studies (Mirzoyan et al., 1989; Lukyanova et al., 1999)
- Product quality varies wildly; only source from vendors publishing third-party COAs (Cohen et al., 2015)
For research targeting calm focus, event anxiolysis, or vascular headache prophylaxis, picamilon stands out for its gentle efficacy and low side effect profile in properly structured protocols.